Programmed Death Ligand 1 Is Overexpressed in Liver Macrophages in Chronic Liver Diseases, and Its Blockade Improves the Antibacterial Activity Against Infections
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Background and Aims: Bacterial infections are common and severe in cirrhosis, but their pathogenesis is poorly understood. Dysfunction of liver macrophages may play a role, but information about their function in cirrhosis is limited. Our aims were to investigate the specific profile and function of liver macrophages in cirrhosis and their contribution to infections. Macrophages from human cirrhotic livers were characterized phenotypically by transcriptome analysis and flow cytometry; function was assessed in vivo by single photon emission computerized tomography in patients with cirrhosis. Serum levels of specific proteins and expression in peripheral monocytes were determined by ELISA and flow cytometry. In vivo phagocytic activity of liver macrophages was measured by spinning disk intravital microscopy in a mouse model of chronic liver injury. Approach and Results: Liver macrophages from patients with cirrhosis overexpressed proteins related to immune exhaustion, such as programmed death ligand 1 (PD‐L1), macrophage receptor with collagenous structure (MARCO), and CD163. In vivo phagocytic activity of liver macrophages in patients with cirrhosis was markedly impaired. Monocytes from patients with cirrhosis showed overexpression of PD‐L1 that paralleled disease severity, correlated with its serum levels, and was associated with increased risk of infections. Blockade of PD‐L1 with anti‐PD‐L1 antibody caused a shift in macrophage phenotype toward a less immunosuppressive profile, restored liver macrophage in vivo phagocytic activity, and reduced bacterial dissemination. Conclusion: Liver cirrhosis is characterized by a remarkable impairment of phagocytic function of macrophages associated with an immunosuppressive transcriptome profile. The programmed cell death receptor 1/PD‐L1 axis plays a major role in the impaired activity of liver macrophages. PD‐L1 blockade reverses the immune suppressive profile and increases antimicrobial activity of liver macrophages in cirrhosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., Abraham, J., Adair, T., Aggarwal, R., Ahn, S. Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61728-0 · Cited by 14,070 · cited 1×
“Liver cirrhosis is the final stage of chronic liver disease and one of the leading causes of death in adults worldwide.(1) Cirrhosis causes a”
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352 · cited 2×
“(17) Importantly, blocking of the PD- 1/PDL1 pathway has been shown to induce immunological response to cancer cells and has carried a change of paradigm for the treatment of different cancers.(16,17)”
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
Garcia-Diaz, A., Shin, D. S., Moreno, B. H., Saco, J., Escuin-Ordinas, H., Rodriguez, G. A., Zaretsky, J. M., Sun, L., Hugo, W., Wang, X., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.04.031 · Cited by 1,942 · cited 4×
“297 marked impairment of the immune system, which is particularly relevant from a clinical perspective because it is responsible for the high risk of bacterial infections of patients with advanced cirrhosis.(24) Bacterial infections account for a large number of hospital admissions and high cost for health care system…”
InfluentialResolving the fibrotic niche of human liver cirrhosis at single-cell level
Ramachandran, P., Dobie, R., Wilson-Kanamori, J. R., Dora, E. F., Henderson, B. E. P., Luu, N. T., Portman, J. R., Matchett, K. P., Brice, M., Marwick, J. A., et al. (2019) · Nature · doi:10.1038/s41586-019-1631-3 · Cited by 1,784 · cited 1×
“Because liver macrophages represent a pool of different cell subpopulations,(21) we aimed to evaluate the expression of PDL1 in liverresident (MARCO+CD163+) and scarassociated (TREM2+CD9+) macrophages from cirrhotic and control livers.”
Cirrhosis-associated immune dysfunction: Distinctive features and clinical relevance
Albillos, A., Lario, M., & Álvarez-Mon, M. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.08.010 · Cited by 1,242
Immunology in the liver — from homeostasis to disease
Heymann, F., & Tacke, F. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.200 · Cited by 1,180
Brown, J. A., Dorfman, D. M., Ma, F.-R., Sullivan, E. L., Munoz, O., Wood, C. R., Greenfield, E. A., & Freeman, G. J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.3.1257 · Cited by 968
Bacterial infections in cirrhosis: A position statement based on the EASL Special Conference 2013
Jalan, R., Fernandez, J., Wiest, R., Schnabl, B., Moreau, R., Angeli, P., Stadlbauer, V., Gustot, T., Bernardi, M., Canton, R., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.01.024 · Cited by 906
Self-citationLiver — guardian, modifier and target of sepsis
Strnad, P., Tacke, F., Koch, A., & Trautwein, C. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.168 · Cited by 692 · cited 1×
“(6,7) It is currently believed that the main mechanisms of this increased rate of infections are related to gut dysbiosis together with marked impairment of defensive mechanisms, particularly those existing in the liver.(25) Nevertheless, despite the major clinical relevance of infections in human cirrhosis, the funct…”
Ju, C., & Tacke, F. (2016) · Cellular & Molecular Immunology · doi:10.1038/cmi.2015.104 · Cited by 554 · cited 1×
“(9) However, information is very limited, and there are no studies assessing the molecular mediators responsible for the impairment of macrophage activity.(10,11) Programmed cell death receptor 1 (PD- 1) and programmed death ligand 1 (PDL1) are checkpoint molecules that suppress immune response.”
Cited by
COVID-19 and liver disease: mechanistic and clinical perspectives
Marjot, T., Webb, G. J., Barritt, A. S., Moon, A. M., Stamataki, Z., Wong, V. W., & Barnes, E. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00426-4 · Cited by 385
Heterogeneity and Function of Kupffer Cells in Liver Injury
Li, W., Chang, N., & Li, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.940867 · Cited by 102
“In human cirrhosis, KC number has been reported to be unchanged (33, 93) while rat KCs are reduced upon cirrhosis (94).”
BackgroundThe Multifaceted Roles of Macrophages in NAFLD Pathogenesis
Vonderlin, J., Chavakis, T., Sieweke, M., & Tacke, F. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.03.002 · Cited by 96
Liver macrophages: development, dynamics, and functions
Nusse, Y., & Kubes, P. (2025) · Cellular & Molecular Immunology · doi:10.1038/s41423-025-01298-3 · Cited by 50
Self-citationGuillot, A., & Tacke, F. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000491 · Cited by 45
Spatial dimension of macrophage heterogeneity in liver diseases
Guillot, A., & Tacke, F. (2023) · eGastroenterology · doi:10.1136/egastro-2023-000003 · Cited by 40
“45 48 More specifically, patients with liver cirrhosis showed reduced liver uptake and plasma disappearance of radiolabelled colloid than healthy subjects.”
Metadata
- Authors
- Pose, E., Coll, M., Martínez‐Sánchez, C., Zeng, Z., Surewaard, B. G. J., Català, C., Velasco‐de Andrés, M., Lozano, J. J., Ariño, S., Fuster, D., Niñerola‐Bazán, A., Graupera, I., Muñoz, É., Lozano, F., Sancho‐Bru, P., Kubes, P., & Ginès, P.
- Venue
- Hepatology
- Published
- 2021-06-02
- Volume
- 74
- Issue
- 1
- Pages
- 296-311
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W3099012122
- Cited by
- 54
- References
- 11
- FWCI
- 2.95
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.